Jenner & Block

"The Biosimilar Regulatory Pathway and the Patent Dance"

The Affordable Care Act introduced a pathway for FDA approval of abbreviated applications for biological products that are shown to be “biosimilar” to an already-approved biologic.  This article discusses the regulatory framework for approving biosimilars, including the procedural provisions of the “patent dance.”